TheBrief.Health

The expiration of enhanced ACA subsidies is driving coverage losses, higher premiums, and underinsurance, increasing uncompensated care while straining patients, providers, and healthcare systems nationwide.

Emerging evidence suggests GLP-1 receptor agonists may reduce alcohol cravings and heavy drinking, offering a promising new treatment approach for alcohol use disorder, especially with obesity.

Endovascular pulmonary artery banding offers a less invasive alternative for selected infants with congenital heart disease, stabilizing pulmonary blood flow while delaying higher-risk open-heart surgery.

A large meta-analysis found people experiencing homelessness receive fewer time-critical stroke treatments, highlighting urgent needs for equitable triage, standardized care pathways, and stronger post-discharge support.

FDA clearance of a 4K fluorescence-guided exoscope enhances open surgery by improving visualization, teamwork, and real-time tissue perfusion assessment to support safer surgical decisions.

Updated pediatric heart guidelines promote earlier screening for sudden cardiac death risk, helping clinicians identify warning signs, order timely testing, and prevent life-threatening cardiac events.

New research suggests ARBs may better preserve long-term cognitive function than ACE inhibitors in some hypertensive adults, supporting more brain-conscious treatment decisions without changing current therapy universally.

Johnson & Johnson’s new FDA-approved EDOF intraocular lens expands cataract surgery options by improving vision across distances, reducing reading-glass dependence, and minimizing common visual disturbances.

New evidence supports sequential pembrolizumab after radiotherapy for high-risk Merkel cell carcinoma, reducing disease recurrence, preventing distant metastases, and reshaping multidisciplinary postoperative treatment strategies.

Heart–brain clinics unite neurologists and cardiologists to identify stroke causes faster, personalize prevention strategies, reduce recurrent strokes, streamline testing, and improve long-term patient outcomes.

A practical tricuspid regurgitation risk score combines symptoms, imaging, labs, and comorbidities to predict prognosis, guide timely referrals, personalize treatment, and improve patient outcomes.

Arizona’s first heart-in-a-box transplant showcases warm perfusion technology, extending donor heart preservation, expanding transplant opportunities, improving organ assessment, and offering hope for patients nationwide awaiting.

New baby food rules require public testing for lead, arsenic, cadmium, and mercury, improving transparency, guiding safer choices, and encouraging manufacturers to reduce contamination.

Large real-world study found no meaningful dementia risk differences between apixaban, edoxaban, and rivaroxaban, supporting DOAC selection based on safety, adherence, renal function, and patient needs.

Large real-world study found apixaban, edoxaban, and rivaroxaban offer similar dementia protection in atrial fibrillation, allowing clinicians to prioritize safety, adherence, and patient-specific factors.

A structured low-GI Mediterranean diet, daily brisk walking, and vitamin D supplementation significantly reduced recurrence risk in HR-positive breast cancer survivors while improving metabolic health.

Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.

FDA’s Red No. 3 ban will phase the dye out of foods and medicines by 2027, prompting reformulations while reassuring consumers about minimal health risk.

Reflow Medical’s retrievable sirolimus-eluting coronary scaffold aims to treat in-stent restenosis without permanent metal, potentially improving vessel healing while preserving future treatment options.

Neurovalens’ Modius platform brings noninvasive neuromodulation into clinical practice, offering home-based FDA-authorized therapies for insomnia, anxiety, PTSD, and weight management, while facing evidence, reimbursement, and adoption challenges.

Menin inhibitors revumenib and ziftomenib target key leukemia-driving mutations, improving remission rates, enabling transplant opportunities, and advancing precision treatment for relapsed acute leukemias.

AI-powered ECG and ultrasound tools can identify silent left ventricular systolic dysfunction earlier, enabling timely evaluation, targeted treatment, and improved heart failure prevention and outcomes.

A new generation of oral HER2-targeted therapies is transforming advanced NSCLC care, delivering durable responses, brain metastasis control, and personalized treatment beyond traditional chemotherapy.

A newly approved c-Met–targeted antibody-drug conjugate offers a precision treatment option for previously treated advanced non-squamous NSCLC, expanding personalized therapy beyond genomic mutations alone.

FDA approval of Tzield marks a breakthrough in Type 1 diabetes care, preserving remaining insulin-producing cells and shifting treatment from replacement to disease modification.